Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology. Mol Oncol, 2025 [Read Here]
p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2025 [Read Here]
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants. European Urology Focus, 2025 [Read Here]
Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer. The Journal of Pathology, 2024 [Read Here]
Low-dose carboplatin modifies the tumour microenvironment to augment CAR T cell efficacy in human prostate cancer models. Nature Communications, 2023 [Read Here]
The future of patient-derived xenografts in prostate cancer research. Nature Reviews Urology, 2023 [Read Here]
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. Nature Communications, 2021 [Read Here]
Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer. Journal of Pathology, 2021 [Read Here]
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018 [Read Here]